Libtayo (Cemiplimab)

cemiplimab 350 mg/7 mL injection, 7 mL vial · INJECTION · PBS code 13162R

STREAMLINED

What it costs

AU$7290 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2022-11-01.
• Repeats: 6.
• PBS program: IN.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Continuing treatment - 3 weekly treatment regimen

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have developed disease progression while being treated with this drug for this condition; AND

The treatment must not exceed a total of 35 cycles or up to 24 months of treatment under both initial and continuing treatment restrictions, whichever comes first.

Sponsor: MEDISON PHARMA AUSTRALIA PTY LIMITED ABN 19 659 723 403

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.